We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

45 hedge funds and large institutions have $8.34M invested in Galectin Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

240% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 5

199% more capital invested

Capital invested by funds: $2.79M → $8.34M (+$5.55M)

188% more call options, than puts

Call options by funds: $784K | Put options by funds: $272K

5% more funds holding

Funds holding: 43 → 45 (+2)

0.94% more ownership

Funds ownership: 9.7% → 10.65% (+0.94%)

Holders
45
Holders Change
+2
Holders Change %
+4.65%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
17
Reduced
5
Closed
2
Calls
$784K
Puts
$272K
Net Calls
+$512K
Net Calls Change
+$449K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$317K
2
Charles Schwab
Charles Schwab
California
+$230K
3
BlackRock
BlackRock
New York
+$195K
4
Morgan Stanley
Morgan Stanley
New York
+$125K
5
DADC
D.A. Davidson & Co
Montana
+$115K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$31K
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$8.82K
3
BCA
Benchmark Capital Advisors
New York
-$6.03K
4
Bank of America
Bank of America
North Carolina
-$5.25K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$1.92K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
$35K +$23K +15,243 New
LWAC
27
Laurel Wealth Advisors (California)
California
$34K +$7.54K +5,000 +50%
State Street
28
State Street
Massachusetts
$27K – – –
GC
29
Guggenheim Capital
Illinois
$27K +$106 +70 +0.6%
Wells Fargo
30
Wells Fargo
California
$27K +$10.8K +7,162 +152%
WAM
31
Wolverine Asset Management
Illinois
$15K – – –
IA
32
IFP Advisors
Florida
$14K – – –
Bank of America
33
Bank of America
North Carolina
$13K -$5.25K -3,480 -37%
IWM
34
IHT Wealth Management
Illinois
$9K +$3.01K +2,000 +100%
UBS Group
35
UBS Group
Switzerland
$9K +$4.32K +2,864 +341%
First Manhattan
36
First Manhattan
New York
$3K – – –
NFG
37
Next Financial Group
Texas
$3K – – –
PRS
38
Pinkerton Retirement Specialists
Idaho
$2K – – –
CG
39
Cutler Group
California
$2K +$151 +100 +10%
RAM
40
Riggs Asset Management
Pennsylvania
$2K +$1.51K +1,000 New
TWA
41
TCI Wealth Advisors
Arizona
$1K – – –
ARTA
42
A.R.T. Advisors
New York
– -$31K -31,740 Closed
Creative Planning
43
Creative Planning
Kansas
– -$509 -338 -69%
1
2

GALT Hedge Fund Activity: Q1 2017 in Review

45 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2017, worth a combined $8.34M — up 199% from $2.79M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new GALT positions and 2 closed out — a net gain of 5 holders — while 17 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $317K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $31K sold.

  • 45 institutional investors held Galectin Therapeutics (GALT) as of Q1 2017, up from 43 in Q4 2016.
  • Funds reported $8.34M of Galectin Therapeutics stock for Q1 2017, up 199% quarter-over-quarter.
  • 7 funds opened new Galectin Therapeutics positions in Q1 2017 and 2 closed out, a net change of +5 holders.
  • The largest Galectin Therapeutics buyer in Q1 2017 was Vanguard Group, an estimated $317K added.
  • The largest Galectin Therapeutics seller in Q1 2017 was A.R.T. Advisors, an estimated $31K sold.

Based on aggregated 13F filings for Q1 2017.